LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers):
holder breadth -10.0% ·
share flow -2.5% ·
net new positions -14.8%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 191 | +4 | 666.78M | $798.87B | +6 | −3 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | n/a |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | n/a |
| Q2 2024 | 22 | n/a | 112.43M | $101.75B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 80.96M | +0.7% | $61.77B | 0.9% | ▲ Add | 2 | SEC ↗ ×7 |
| 2 | BlackRock ✦ (passive) | 65.81M | -0.2% | $50.21B | 0.9% | ▼ Trim | 2 | SEC ↗ ×23 |
| 3 | State Street Global Advisors ✦ (passive) | 34.73M | +0.6% | $26.50B | 0.9% | ▲ Add | 4 | SEC ↗ |
| 4 | Fidelity (FMR) ✦ | 24.17M | -5.7% | $18.44B | 1.0% | ▼ Trim | 2 | SEC ↗ ×6 |
| 5 | JPMorgan Chase ✦ | 20.54M | n/a | $15.67B | 0.5% | n/c | 1 | SEC ↗ ×44 |
| 6 | Geode Capital Management ✦ (passive) | 19.82M | +9.3% | $15.07B | 1.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Morgan Stanley ✦ | 15.19M | n/a | $11.59B | 0.7% | n/c | 1 | SEC ↗ ×24 |
| 8 | Capital World Investors ✦ | 14.97M | -15.1% | $11.42B | 1.6% | ▼ Trim | 6 | SEC ↗ |
| 9 | Wellington Management ✦ | 14.56M | +4.1% | $11.11B | 1.9% | ▲ Add | 6 | SEC ↗ ×9 |
| 10 | T. Rowe Price ✦ | 13.48M | -20.0% | $10.28B | 1.1% | ▼ Trim | 6 | SEC ↗ ×2 |
| 11 | PRIMECAP Management ✦ | 10.80M | -11.2% | $8.24B | 6.3% | ▼ Trim | 6 | SEC ↗ |
| 12 | Goldman Sachs Group ✦ | 6.65M | n/a | $5.08B | 0.7% | n/c | 1 | SEC ↗ ×6 |
| 13 | Fisher Asset Management ✦ | 4.45M | +3.5% | $3.40B | 1.2% | ▲ Add | 6 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 1.15M | +35.1% | $879.60M | 0.7% | ▲ Add | 6 | SEC ↗ ×2 |
| 15 | Adage Capital Partners ✦ | 806.87K | -4.2% | $615.64M | 1.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 488.63K | -7.5% | $372.82M | 0.3% | ▼ Trim | 6 | SEC ↗ ×2 |
| 17 | AQR Capital Management ✦ | 451.18K | +30.0% | $330.82M | 0.2% | ▲ Add | 6 | SEC ↗ ×6 |
| 18 | Millennium Management ✦ | 300.26K | -47.4% | $229.10M | 0.2% | ▼ Trim | 6 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 200.91K | +172.4% | $153.29M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 20 | Marshall Wace ✦ | 163.09K | -82.5% | $124.43M | 0.1% | ▼ Trim | 6 | SEC ↗ ×3 |
| 21 | Arrowstreet Capital ✦ | 100.40K | New | $76.61M | 0.0% | New | 1 | SEC ↗ |
| 22 | Dodge & Cox ✦ | 43.38K | -3.5% | $33.10M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 23 | GAMCO Investors ✦ | 24.98K | -8.8% | $19.06M | 0.2% | ▼ Trim | 6 | SEC ↗ |
| 24 | Bridgewater Associates ✦ | 10.44K | New | $7.97M | 0.0% | New | 1 | SEC ↗ |
| 25 | Gotham Asset Management ✦ | 8.02K | +11.6% | $6.12M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 26 | Point72 Asset Management ✦ | 7.12K | -96.2% | $5.43M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 27 | Harris Associates (Oakmark) ✦ | 414 | 0.0% | $315,882 | 0.0% | Held | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $76.61M | 0.0% |
| Bridgewater Associates | $7.97M | 0.0% |
Exited
| Norges Bank | $8.83B | was 1.1% |
| Tiger Global Management | $1.18B | was 3.5% |
| Viking Global Investors | $325.00M | was 0.9% |
| Coatue Management | $91.53M | was 0.3% |
| Duquesne Family Office | $78.48M | was 2.0% |
| Renaissance Technologies | $204,662 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 4,323 holders, 762.84M shares, $674.93B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 6.50K sh · $7.64M
Officer · 2.00K sh · $2.37M
Officer · 5.00K sh · $5.95M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology